Gil Roth07.30.13
Pfizer 2Q13
2Q Revenues: $13.0 billion (-7%)
2Q Earnings: $14.1 billion (+333%)*
YTD Revenues: $25.4 billion (-9%)
YTD Earnings: $16.9 billion (+234%)*
Comments: Lipitor sales worldwide dropped nearly $700 million in 2Q13 to $545 million (-55%), while overall pharma revenues fell $1.0 billion (-8%) to $12.1 billion. Lyrica posted a 10% gain to $1.1 billion, while changes in buying patterns led to a 3% drop for Prevnar vaccines ($970 million). New drugs Inlyta and Xalkori posted revenues of $71 million and $67 million, respectively. In its first quarter, Xeljanz reported $22 million in sales. The Pfizer CentreSource unit, which provides contract manufacturing and bulk pharma chemical sales, posted revenues of $63 million in the quarter, up 5%. PCS revenues for YTD are $116 million (+3%)
* Earnings include $10.5 billion (pre-tax) from spinning off its Zoetis Animal Health business.
2Q Revenues: $13.0 billion (-7%)
2Q Earnings: $14.1 billion (+333%)*
YTD Revenues: $25.4 billion (-9%)
YTD Earnings: $16.9 billion (+234%)*
Comments: Lipitor sales worldwide dropped nearly $700 million in 2Q13 to $545 million (-55%), while overall pharma revenues fell $1.0 billion (-8%) to $12.1 billion. Lyrica posted a 10% gain to $1.1 billion, while changes in buying patterns led to a 3% drop for Prevnar vaccines ($970 million). New drugs Inlyta and Xalkori posted revenues of $71 million and $67 million, respectively. In its first quarter, Xeljanz reported $22 million in sales. The Pfizer CentreSource unit, which provides contract manufacturing and bulk pharma chemical sales, posted revenues of $63 million in the quarter, up 5%. PCS revenues for YTD are $116 million (+3%)
* Earnings include $10.5 billion (pre-tax) from spinning off its Zoetis Animal Health business.
